HealioDrug combination acts against aggressive chronic lymphocytic leukemiaOutcome Magazine (blog)12/10/2012 A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound res…
ESME Think Tank Closing; Donations Go to ME Rituximab ProjectProHealthESME's website [http://esme-eu.com] will be accessible for approximately 1 year, but no new information will be added. The donations that were given to ESME will be given to a pr…
Trial of 5-Minute Subcutaneous Rituximab Injection: Positive ResultsProHealthDec 8: Basil, Switzerland-based Roche pharmaceuticals company reports positive results from two international phase III trials of its MabThera – a form of rituximab that can…
Imprime PGG in Combination with Monoclonal Antibody Therapy Achieves 64 …PharmaLive (press release) (subscription)(BUSINESS WIRE)–Dec 10, 2012 – All subjects in a phase 1 study of high risk, chronic lymphocytic leukemia responded to the combination …
Imprime PGG in Combination with Monoclonal Antibody Therapy Achieves 64 …MarketWatch (press release)Research shows that early monoclonal antibody (mAb) therapy with alemtuzumab and rituximab is effective and could possibly delay first standard treatm…
TG Therapeutics, Inc. Announces Poster Presentation Highlights for Ublituximab …GlobeNewswire (press release)In vitro / in vivo results demonstrate superior efficacy with ublituximab compared to rituximab in primary central nervous system lymphomas, …
TG Therapeutics, Inc. Announces Poster Presentation Highlights for Ublituximab …MarketWatch (press release)In vitro / in vivo results demonstrate superior efficacy with ublituximab compared to rituximab in primary central nervous system lymphomas, in…
Rituximab Benefits Some APS Non-Criteria ManifestationsMonthly Prescribing Reference(HealthDay News) – Some patients with antiphospholipid syndrome with non-criteria manifestations may improve after treatment with rituximab, according to a study publ…
TODAY ON PHARMALIVE.COMPharmaLive (press release) (subscription)With a demonstrated ability to induce significantly greater ADCC activity over rituximab, TG-1101 is uniquely positioned to take advantage of the NK-cell activating properties exhibited by…
HealioIbrutinib Effective and Safe Treatment Option in CLLMedscapeAlthough chemoimmunotherapy approaches such as fludarabine, cyclophosphamide, and rituximab have markedly improved outcomes, primarily of younger, fit patients, fludarabine-based therapy…